ライフサイエンスコーパス: hyperthyroidism

1 ct suppressed levels of TSH (<0.4 mIU L(-1); hyperthyroidism).

2 requent cause is Graves' disease (autoimmune hyperthyroidism).

3 1 reversible immune-related AE (thyroiditis, hyperthyroidism).

4 yperthyroidism) or within range (subclinical hyperthyroidism).

5 ormation for planning radioiodine therapy of hyperthyroidism.

6 IU L(-1) indicating clinical significance of hyperthyroidism.

7 bclinical hypothyroidism and 671 subclinical hyperthyroidism.

8 is the preferred choice for relapsed Graves' hyperthyroidism.

9 ypothyroidism and 648 (2.6%) had subclinical hyperthyroidism.

10 and resolve with treatment of the underlying hyperthyroidism.

11 Atrial fibrillation frequently complicates hyperthyroidism.

12 ce would facilitate AF in autoimmune Graves' hyperthyroidism.

13 nesis of atrial fibrillation (AF) in Graves' hyperthyroidism.

14 pproach to distinguishing different forms of hyperthyroidism.

15 erican patients treated with radioiodine for hyperthyroidism.

16 hyroidism, and 1.5% (n = 47) had subclinical hyperthyroidism.

17 -induced thyroid dysfunction) and factitious hyperthyroidism.

18 dermatitis, vitiligo, panhypopituitarism and hyperthyroidism.

19 to the thyrotropin receptor (TSHR) and cause hyperthyroidism.

20 nal treatments for the three common forms of hyperthyroidism.

21 ity in patients treated with radioiodine for hyperthyroidism.

22 ceptor and carbimazole-responsive autoimmune hyperthyroidism.

23 ay activated in cancer cachexia, sepsis, and hyperthyroidism.

24 tios (SMRs) after 3 treatment modalities for hyperthyroidism.

25 all, (131)I appears to be a safe therapy for hyperthyroidism.

26 3 yr developed enlargement of the nodule and hyperthyroidism.

27 mune hyperthyroidism and sporadic congenital hyperthyroidism.

28 P=5.4x10(-5)) for genetic predisposition to hyperthyroidism.

29 o the elevated serum ferritin levels seen in hyperthyroidism.

30 ute to 131I therapy failure in patients with hyperthyroidism.

31 ted in some patients with hypothyroidism and hyperthyroidism.

32 drug induced) causes thyrotoxicosis without hyperthyroidism.

33 ancer and age-of-onset of hypothyroidism and hyperthyroidism.

34 n which they are implicated, i.e., hypo- and hyperthyroidism.

35 xia, duodenitis, increased transaminases and hyperthyroidism.

36 show alopecia, eyelid inflammation, and mild hyperthyroidism.

37 adult patients with and without preoperative hyperthyroidism.

38 to surgery or to treat inoperable cancer and hyperthyroidism.

39 TDCIPP exposures are associated with feline hyperthyroidism.

40 y and 117 patients with subclinical or overt hyperthyroidism.

41 to the fetus and can cause fetal or neonatal hyperthyroidism.

42 roid adenomas (ATAs) are a frequent cause of hyperthyroidism.

43 itoring or offered alternative treatment for hyperthyroidism.

44 nctions such as Graves disease and hypo- and hyperthyroidism.

45 ion of type 1 from type 2 amiodarone-induced hyperthyroidism.

46 and surgical interventions for management of hyperthyroidism.

47 argets for therapeutic treatment of hypo- or hyperthyroidism.

48 ve been reported in elderly individuals with hyperthyroidism.

49 vity, and the occurrence of tissue damage in hyperthyroidism.

50 cy, neonatal thyrotoxicosis, and post-partum hyperthyroidism.

51 osensitivity (25%-75%), hypothyroidism (6%), hyperthyroidism (0.9%-2%), pulmonary toxicity (1%-17%),

52 - 0.17 to 0.76, I(2) = 15.6) or subclinical hyperthyroidism (- 0.10, 95% confidence interval = - 0.6

53 ism (1), therapeutic abortion (1), worsening hyperthyroidism (1), congestive heart failure (1), and w

54 on (1.43, 1.21-1.69; p<0.0001), but not with hyperthyroidism (1.22, 0.96-1.55; p=0.1010) or raised ad

55 3,512 singleton deliveries of which 0.2% had hyperthyroidism, 1.4% primary and 0.1% iatrogenic hypoth

56 se events were hypothyroidism (25 [16%]) and hyperthyroidism (17 [11%]).

57 es (4 studies: HR, 1.53; 95% CI, 1.27-1.85), hyperthyroidism (3 studies: HR, 1.15; 95% CI, 1.06-1.26)

58 ying thyroid disease was distributed between hyperthyroidism (52%), hypothyroidism (17.6%) and euthyr

59 Hypothyroidism (14.2%) and hyperthyroidism (7.1%) were the most common immune-media

60 ly female (86.7% [26/30]), with a history of hyperthyroidism (96% 29/30).

61 Graves' hyperthyroidism, a common autoimmune disease caused by p

62 Treatment of hyperthyroidism, a common clinical condition that can ha

63 Hyperthyroidism, a condition associated with excess TH,

64 When present in patients with Graves' hyperthyroidism, AAbeta1AR and AAM2R facilitate developm

65 Clinical hyperthyroidism accelerates bone resorption without comp

66 Overt and subclinical hyperthyroidism affected 0.26% and 0.78%, respectively.

67 Graves' disease is the leading cause of hyperthyroidism affecting 1.0-1.6% of the population.

68 Hyperthyroidism affects 2.5% of adults worldwide and is

69 ly removed parathyroid glands, and recurrent hyperthyroidism after 12 months.

70 hyroidectomy 32 yr ago developed accelerated hyperthyroidism after injection of iodinated contrast me

71 tions with antibody-positive hypothyroidism, hyperthyroidism, AIT, or elevated ATPO.

72 ganochlorines and risk of hypothyroidism and hyperthyroidism among female spouses (n = 16,529) in Iow

73 of treatment, early and effective control of hyperthyroidism among patients with Graves' disease is a

74 pairment, diabetes, obesity, hypothyroidism, hyperthyroidism, anaemia, respiratory disease, liver dis

75 5% CI, 1.09-1.65) for those with subclinical hyperthyroidism and 0.90 (95% CI, 0.77-1.05) for those w

76 re is pathophysiologically similar to feline hyperthyroidism and can be caused by chronically low or

77 data show an association between subclinical hyperthyroidism and development of atrial fibrillation b

78 ered therapeutic activity of (131)I to treat hyperthyroidism and euthyroid multinodular goiter.

79 This study suggests that both exogenous hyperthyroidism and exogenous hypothyroidism were associ

80 The association between subclinical hyperthyroidism and fracture risk is less clear.

81 ew discoveries in the pathogenesis of Graves hyperthyroidism and Graves orbitopathy that offer severa

82 Hashimoto's thyroiditis are more common than hyperthyroidism and Graves' disease (strong evidence).

83 Hyperthyroidism and hypothyroidism often cause opposing

84 nd blocking Abs in the sera of patients with hyperthyroidism and hypothyroidism, respectively.

85 mmune diseases of the thyroid gland, causing hyperthyroidism and hypothyroidism, respectively.

86 ically relevant findings that accompany both hyperthyroidism and hypothyroidism.

87 ctive strategies exist for the management of hyperthyroidism and hypothyroidism; these should be tail

88 ementation might lead to faster remission of hyperthyroidism and improved quality of life and eye inv

89 It is the most common cause of hyperthyroidism and occurs at all ages but especially in

90 Hyperthyroidism and primary hypothyroidism were associat

91 ce or amplify the immune response leading to hyperthyroidism and provide new insight into the etiolog

92 is useful to characterize different forms of hyperthyroidism and provides information for planning ra

93 ns have been found in familial nonautoimmune hyperthyroidism and sporadic congenital hyperthyroidism.

94 Subclinical thyroid diseases--subclinical hyperthyroidism and subclinical hypothyroidism--are comm

95 alth outcomes, and management of subclinical hyperthyroidism and subclinical hypothyroidism.

96 mmon abnormality with other abnormalities of hyperthyroidism and thyroiditis.

97 Other causes of hyperthyroidism and thyrotoxicosis include toxic nodules

98 Overall, hyperthyroidism and use of thyroid hormone to suppress T

99 HR by autoantibodies causes Graves' disease (hyperthyroidism) and hypothyroidism, both of which affec

100 93.0% had euthyroidism, 2.6% had subclinical hyperthyroidism, and 4.4% had subclinical hypothyroidism

101 an increased odds ratio for hypothyroidism, hyperthyroidism, and antithyroid antibodies.

102 common endocrine diseases, type 1 diabetes, hyperthyroidism, and hypothyroidism, are the result of a

103 , childbirth or breast feeding, a history of hyperthyroidism, and progestin use were not associated w

104 toimmune diseases, including hypothyroidism, hyperthyroidism, and rheumatoid arthritis, also type-2 d

105 any catabolic states (including denervation, hyperthyroidism, and sepsis) is due to a proteasome-depe

106 sex, race and ethnicity, hyperopia, myopia, hyperthyroidism, and systemic disease burden defined by

107 mented in individuals with hypothyroidism or hyperthyroidism, and these adverse effects can affect he

108 of the signs and symptoms of hypothyroidism, hyperthyroidism, and thyroid nodules, as well as the gen

109 onsidered included diabetes, hypothyroidism, hyperthyroidism, and vitiligo.

110 ?"; on what date RAI was first used to treat hyperthyroidism; and why 2 articles on the first use of

111 The most common etiologies of hyperthyroidism are autoimmune hyperthyroidism (Graves d

112 diabetes mellitus, hyperparathyroidism, and hyperthyroidism are considered within the context of bot

113 Subclinical hypothyroidism and hyperthyroidism are diagnoses based on laboratory evalua

114 d side effects after radioiodine therapy for hyperthyroidism are hypothyroidism and a minimal risk of

115 Typical laboratory findings in patients with hyperthyroidism are low TSH, elevated free-thyroxine and

116 low serum TSH levels, indicating physiologic hyperthyroidism, are at increased risk for new hip and v

117 as TSH of 4.5 to 19.9 mIU/L, and subclinical hyperthyroidism as TSH <0.45 mIU/L, the last two with no

118 of untreated subclinical hypothyroidism and hyperthyroidism, as well as the benefit of initiating tr

119 As a consequence, both hypothyroidism and hyperthyroidism associate with clinically important alte

120 cross-sectional analysis of hypothyroidism, hyperthyroidism, autoimmune thyroiditis (AIT), serum con

121 isease is an autoimmune disorder that causes hyperthyroidism because of autoantibodies that bind to t

122 in several clinical and biochemical signs of hyperthyroidism between baseline and 12 months of treatm

123 y studies evaluated treatment of subclinical hyperthyroidism but examined intermediate outcomes.

124 is safe and effective in most patients with hyperthyroidism but not all individuals are cured by the

125 sed increasingly as first-line treatment for hyperthyroidism, but concerns remain about subsequent ri

126 The risk of AF is increased in subclinical hyperthyroidism, but it is uncertain whether variations

127 injecting TSHR A-subunit protein attenuated hyperthyroidism by diverting pathogenic TSHR Abs to a no

128 By contrast, hyperthyroidism can be accompanied by profound weight lo

129 Fetal hyperthyroidism can be life-threatening, and needs to be

130 Hyperthyroidism can be treated with oral antithyroid dru

131 Untreated hyperthyroidism can cause cardiac arrhythmias, heart fai

132 Hyperthyroidism causes increased energy intake and expen

133 crease in basal metabolic rate is not due to hyperthyroidism, compensation by the widely expressed un

134 o-moderate intensity, including two cases of hyperthyroidism consistent with autoimmune thyroiditis.

135 elevations due to low TSH signaling in human hyperthyroidism contribute to the bone loss that has tra

136 Subclinical hyperthyroidism, defined as low concentrations of thyrot

137 Overt hyperthyroidism, defined as suppressed thyrotropin (prev

138 ve cohort study, we identified patients with hyperthyroidism, diagnosed between Jan 1, 1998, and Dec

139 Acute hyperthyroidism did not affect graft function, but acute

140 Hyperthyroidism did not significantly alter MDA-protein

141 classic clinical triad of Graves' disease is hyperthyroidism, diffuse goiter, and exophthalmos.

142 main, found in a male infant with congenital hyperthyroidism due to a toxic adenoma.

143 Hyperthyroidism due to thyroid-stimulating hormone-secre

144 Other important causes include toxic nodular hyperthyroidism, due to the presence of one or more auto

145 On the other hand, hyperthyroidism during pregnancy has been associated wit

146 n pregnancy, the diagnosis and management of hyperthyroidism during pregnancy, severe life-threatenin

147 ore prevalent in children born to women with hyperthyroidism during pregnancy, suggesting a role for

148 ease or arrhythmia), patients with exogenous hyperthyroidism (eg, thyrotropin levels, <0.1 mIU/L: adj

149 sm in pregnancy can be caused by any type of hyperthyroidism--eg, toxic multinodular goitre or solita

150 o thyroid function test results: subclinical hyperthyroidism, euthyroidism, subclinical hypothyroidis

151 enzyme activity are elevated in the liver in hyperthyroidism, fasting, and diabetes.

152 healthy and sick cats diagnosed with Feline Hyperthyroidism (FH).

153 Feline hyperthyroidism (FHT) is a debilitating disease affectin

154 therapy is a routine procedure of treatment hyperthyroidism for over 50 years.

155 Treatment options for overt hyperthyroidism from autonomous thyroid nodules or Grave

156 The other patient manifested hyperthyroidism from stimulation of the tumors by thyroi

157 les on the first use of RAI for treatment of hyperthyroidism, from 2 different sets of authors from t

158 etiologies of hyperthyroidism are autoimmune hyperthyroidism (Graves disease, GD), toxic multinodular

159 nterest as the primary antigen in autoimmune hyperthyroidism (Graves' disease) caused by stimulating

160 hyroid drug group, radioiodine with resolved hyperthyroidism group (radioiodine group A), or radioiod

161 ine group A), or radioiodine with unresolved hyperthyroidism group (radioiodine group B).

162 ifferences were seen between the subclinical hyperthyroidism group and euthyroidism group for inciden

163 l fibrillation, individuals with subclinical hyperthyroidism had a greater incidence of atrial fibril

164 Cats being treated for hyperthyroidism had lower hair iodine.

165 The osteoporosis associated with human hyperthyroidism has traditionally been attributed to ele

166 or recurrent thyroid cancer, or therapy for hyperthyroidism have been calculated and summarized in t

167 No trials of treatment of subclinical hyperthyroidism have been done.

168 on bone and suggested that the bone loss in hyperthyroidism, hitherto attributed solely to elevated

169 hazard ratio [HR], 6.6; 95% CI, 5.6 to 7.8), hyperthyroidism (HR, 1.8; 95% CI, 1.2 to 2.8), thyroid n

170 shing syndrome (HR, 11.8; 95% CI, 1.4-97.2), hyperthyroidism (HR, 6.3; 95% CI, 2.0-19.5), hypothyroid

171 s in a further increase in the prevalence of hyperthyroidism if iodine intake is subsequently increas

172 Compared to euthyroid rats, hyperthyroidism in 4-month-old rats was associated with

173 These mice showed severe hyperthyroidism in a manner very similar to that describ

174 Identification of hyperthyroidism in a pregnant woman is important because

175 olonged course leads to remission of Graves' hyperthyroidism in about a third of cases.

176 es that 131I treatment for thyroid cancer or hyperthyroidism in adult women confers negligible risk o

177 cal and undiagnosed overt hypothyroidism and hyperthyroidism in adults without goiter or thyroid nodu

178 sease is the most common cause of persistent hyperthyroidism in adults.

179 thyrotropin receptor Abs are responsible for hyperthyroidism in GD.

180 Graves disease is the most common cause of hyperthyroidism in iodine-sufficient areas.

181 afish a very useful model to study hypo- and hyperthyroidism in other vertebrate taxa, including huma

182 HR) (TSAbs) that induce a sustained state of hyperthyroidism in patients.

183 n the prevalence of toxic nodular goitre and hyperthyroidism in populations.

184 Thyroid storm and hyperthyroidism in pregnancy and during the post-partum

185 utoimmune in nature, is the usual cause; but hyperthyroidism in pregnancy can be caused by any type o

186 Antithyroid drug treatment of hyperthyroidism in pregnant women is controversial becau

187 Treatment options for hyperthyroidism include antithyroid drugs, radioactive i

188 The more unusual causes of hyperthyroidism, including struma ovarii, thyrotropin-se

189 Although it is established that hyperthyroidism increases AF incidence, the effect of hy

190 Hyperthyroidism increases heart rate, contractility, car

191 Specifically, hyperthyroidism increases the ex vivo activity of pyruva

192 Hyperthyroidism induced by injection of normal rats with

193 Hyperthyroidism induced by T3 treatment caused up-regula

194 index, bariatric surgery, eating disorders, hyperthyroidism, inflammatory bowel disease, rheumatoid

195 Hyperthyroidism is a common endocrinopathy of domestic f

196 Hyperthyroidism is a pathological syndrome in which tiss

197 Hyperthyroidism is associated with increased metabolic r

198 Prolonged hyperthyroidism is best avoided.

199 Graves' hyperthyroidism is caused by autoantibodies to the thyro

200 Hyperthyroidism is characterised by increased thyroid ho

201 normal serum FT4 concentration; subclinical hyperthyroidism is defined as a decrease in serum TSH be

202 The diagnosis of hyperthyroidism is generally straightforward, with raise

203 The most common cause of hyperthyroidism is Graves disease, with a global prevale

204 The most common cause of hyperthyroidism is Graves' disease, followed by toxic no

205 Although hyperthyroidism is known to increase the risk of atrial

206 The aetiopathogenesis of feline hyperthyroidism is not known, but chronically low or flu

207 Because Graves' hyperthyroidism is preferentially induced in BALB/c mice

208 Treatment for subclinical hyperthyroidism is recommended for patients at highest r

209 Although Graves hyperthyroidism is relatively common, no causal treatmen

210 Feline hyperthyroidism is the most commonly diagnosed endocrine

211 The osteoporosis associated with hyperthyroidism is traditionally viewed as a secondary c

212 Hyperthyroidism is treated with antithyroid drugs, radio

213 Both hypothyroidism and hyperthyroidism lead to increased AF vulnerability in a

214 Endogenous hyperthyroidism may be a risk factor for dementia, but d

215 Biochemical evidence of hyperthyroidism may be associated with low bone mass, pa

216 or recurrent thyroid cancer, or therapy for hyperthyroidism may be treated with 7400 MBq (200 mCi) 1

217 At the other end of the spectrum, hyperthyroidism may result from gain of function mutatio

218 arly step in a pathologic cascade leading to hyperthyroidism, metabolic bone disease, vascular calcif

219 Subclinical hyperthyroidism might be associated with an increased ri

220 Meanwhile, subclinical hyperthyroidism mirrored that pattern.

221 Thus, the appropriate management of hyperthyroidism, most commonly caused by Graves disease,

222 ne concentrations that are characteristic of hyperthyroidism must be distinguished from physiological

223 Neither hyperthyroidism nor (131)I treatment resulted in a signi

224 pproximately one to two cases of gestational hyperthyroidism occur per 1000 pregnancies.

225 el of Graves disease to show that goiter and hyperthyroidism occur to a much greater extent when the

226 rmone levels, ranging from hypothyroidism to hyperthyroidism on AF inducibility in thyroidectomized r

227 assess the long-term effects of subclinical hyperthyroidism on mortality.

228 tropin receptor (TSHR), the cause of Graves' hyperthyroidism, only develop in humans.

229 for colitis (0.46, 0.27-0.76, p=0.0026) and hyperthyroidism or hypothyroidism (0.63, 0.44-0.90, p=0.

230 the hypothesis that unrecognized subclinical hyperthyroidism or subclinical hypothyroidism is associa

231 ion of the receptor, resulting in congenital hyperthyroidism or the development of actively secreting

232 Women with a history of hyperthyroidism or TSH suppression by thyroid hormone sh

233 was the only pesticide associated with both hyperthyroidism (OR(adj) = 2.3 (95% CI: 1.2, 4.4) and hy

234 ; odds ratio [OR], 1.86; 95% CI, 1.56-2.22), hyperthyroidism (OR, 9.04; 95% CI, 6.75-12.11), ordering

235 g, pulmonary embolism, anemia, infection, or hyperthyroidism) or be related to several incompletely d

236 nine concentrations, which are raised (overt hyperthyroidism) or within range (subclinical hyperthyro

237 e pregnant, had diagnosed hypopituitarism or hyperthyroidism, or had a medical condition or used medi

238 ardiomyopathy, significant valvular disease, hyperthyroidism, or hypertension that preceded the onset

239 bunit adenovirus failed to develop TSHR Abs, hyperthyroidism, or splenocyte responses to TSHR Ag.

240 ted for thyroid cancer were less compared to hyperthyroidism patients.

241 Hypothyroidism and hyperthyroidism produced opposite electrophysiological c

242 Of the covariates, only hyperthyroidism prolonged by at least 2.5 mo was signifi

243 uated interactions of 6 covariates-prolonged hyperthyroidism, prolonged hypothyroidism, smoking, trea

244 apnea, obesity, excessive alcohol, smoking, hyperthyroidism, pulmonary disease, air pollution, and p

245 apnea, obesity, excessive alcohol, smoking, hyperthyroidism, pulmonary disease, air pollution, heart

246 en in 4 patients (grade 3 arthritis, grade 2 hyperthyroidism, recurrent grade 4 pneumonitis).

247 Hyperthyroidism refers to increased thyroid hormone synt

248 Appropriate treatment of hyperthyroidism relies on identification of the underlyi

249 affects 50% to 60% of patients with Graves' hyperthyroidism, resulting in exophthalmos, periorbital

250 pes of inflammatory disease (hypothyroidism, hyperthyroidism, rheumatoid arthritis) associated with r

251 fter adjustment for age, history of previous hyperthyroidism, self-rated health, and use of estrogen

252 ake whereas productive thyrotoxicosis (i.e., hyperthyroidism "sensu strictu") is characterized by hig

253 Rapid and sustained control of hyperthyroidism should be prioritised in the management

254 Individuals with hypo- or hyperthyroidism showed various changes in electrocardiog

255 g and tissue thyroid hormone levels, whereas hyperthyroidism specifically denotes disorders involving

256 TSH level may contribute to the bone loss of hyperthyroidism that has been attributed traditionally t

257 ing the disease states of hypothyroidism and hyperthyroidism, the development and treatment of which

258 diabetes mellitus, hyperparathyroidism, and hyperthyroidism), they should be considered in the diffe

259 th Part 1 (which dealt with various forms of hyperthyroidism), this article is intended to provide re

260 patients with subclinical hypothyroidism and hyperthyroidism through 5 case scenarios that apply the

261 ls compared risks of primary hypothyroidism, hyperthyroidism, thyroid neoplasms, hypopituitarism, obe

262 assessment, and treatment of hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer in

263 5 mIU/L; FT4 level, 0.7-1.9 ng/dL; exogenous hyperthyroidism: thyrotropin level, <0.5 mIU/L; FT4 leve

264 and monitoring of patients with subclinical hyperthyroidism to prevent bone mineral disease.

265 vity (AA, in MBq) for the thyroid cancer and hyperthyroidism treatment groups were 4244 2021 (1669-80

266 In an important study of Graves hyperthyroidism, treatment with radioactive iodine was m

267 Rates of new onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09-0.61; p

268 atios (HRs) of participants with subclinical hyperthyroidism versus euthyrodism were 1.38 (95% CI, 0.

269 aring participants with subclinical hypo- or hyperthyroidism versus euthyroidism, adjusting for depre

270 oping postthyroidectomy hypocalcemia include hyperthyroidism, vitamin D deficiency, female sex, subst

271 12.5%, and prevalence of hypothyroidism and hyperthyroidism was 6.9% and 2.1%, respectively.

272 Hyperthyroidism was also associated with rare outcomes (

273 based cohort study suggests that subclinical hyperthyroidism was an independent risk factor associate

274 After adjustment for TSH level, a history of hyperthyroidism was associated with a twofold increase i

275 It was assumed the hyperthyroidism was caused by evolving toxicity in the a

276 Subclinical hyperthyroidism was defined as a thyrotropin level lower

277 et containing 0.15% propyl-2-thiouracil, and hyperthyroidism was generated by addition of L-thyroxine

278 Hyperthyroidism was induced by daily injection of l-3,5,

279 Hyperthyroidism was induced in 18 male Wistar rats with

280 A history of hyperthyroidism was not significantly related to HCC (OR

281 the nodule had undergone infarction and the hyperthyroidism was secondary to Graves' disease.

282 and 24 [26%] patients, respectively), while hyperthyroidism was unknown in 29 patients (32%) before

283 ergy homeostasis in response to experimental hyperthyroidism, we administered 200 mug tri-iodothyroni

284 er low TSH levels contribute to bone loss in hyperthyroidism, we compared the skeletal phenotypes of

285 d, the HRs for participants with subclinical hyperthyroidism were 2.16 (CI, 0.87 to 5.37) for hip fra

286 th subclinical hypothyroidism or subclinical hyperthyroidism were also included (n=23).

287 atrial fibrillation and progression to overt hyperthyroidism were rated as good, but no data supporte

288 icted thyroid-stimulating hormone levels and hyperthyroidism were statistically significantly associa

289 eurodevelopmental impairments and peripheral hyperthyroidism, whereas OATP1C1 deficiency is linked to

290 Using iatrogenic hyperthyroidism, whether during treatment for hypothyroi

291 lin G purified from 38 patients with Graves' hyperthyroidism with AF (n=17) or sinus rhythm (n=21) an

292 ne levels in the direction of a mild form of hyperthyroidism with an increased risk of atrial fibrill

293 ease and the inability to cure toxic nodular hyperthyroidism with antithyroid drugs alone, radioiodin

294 incidence and mortality in those treated for hyperthyroidism with radioiodine is reassuring.

295 en reported after treatment of patients with hyperthyroidism with radioiodine.

296 These mice developed severe hyperthyroidism with significant elevations in both tetr

297 is the treatment of choice in most cases of hyperthyroidism, with a standard 7,000-cGy (rad) thyroid

298 Cardiac hypertrophy is another effect of hyperthyroidism, with an increase in the abundance of mi